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Mitochondria are cytoplasmic organelles present in eukaryotic cells that serve as major source of
cellular energy produced through oxidative phosphorylation and thus also known as the power
plants of eukaryotic cells. A distinct feature of mitochondria is its capacity to regenerate owing
to own set of genomic material containing 37 genes. It is now well-known that mutations in
mitochondrial DNA can cause many inherited diseases including ones that affects neurons and
nervous systems. Importantly, in contrast to other cells, neuron rely heavily upon mitochondria
due to their inability to derive sufficient energy though glycolysis (Wallace et al., 2010). As a
results mitochondrial dysfunction severely affects neuronal cells and proved to be central in the
pathogenesis of many neurodegenerative diseases such as Amyotrophic lateral sclerosis (ALS),
Parkinson’s disease (PD), Huntington’s disease (HD), Alzheimer’s disease (AD) and many others
(Johri and Beal, 2012). According to Friedrich Max Müller, Mitochondria’s are “Advaya” ( )
which in Sanskrit means unique and in Upanishads it means ultimate (Max Müller, 1823–1990).
Mitochondria are cell’s energy factories, divide, multiply, manufacture ATP to fuel all of life’s
activities. Mitochondrial DNA replacement has been successful in mice and primates and with the
refinement of MRT, we hope that it becomes a reality in human. There are more than∼700 known
disease-associated mitochondrial DNA (mtDNA) mutations (mitomap.org). Up to 4000 children
per year in the US are born with inherited mtDNA disorders (Schaefer et al., 2008).
In recent years, major advances in the field of nuclear transfer techniques offer the possibility
to transfer the nuclear material from one cells with damaged and dysfunctional mitochondria
to into another cell only containing cytoplasmic material resulted from careful removal of
the nuclear material before the transfer. Such transfer gives rise to cells where damaged and
dysfunctional mitochondria gets replaced by healthy mitochondria from the donor cells keeping
Abbreviations: AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; CRISPR/Cas, clustered regularly interspaced
short palindromic repeats and CRISPR-associated; fALS, familial amyotrophic lateral sclerosis; FDA, food and drug
administration; HD, Huntington’s disease; HFEA, human fertilization and embryology authority; MRT, mitochondrial
replacement technique; mHTT, mhuntingtin; mtDNA, mitochondrial DNA; mSOD1, mutant superoxide dismutase 1; MNs,
motor neurons; MND, motor neuron disease; MQC, mitochondrial quality control; PD, Parkinson’s disease; PINK1, PTEN-
induced putative kinase 1; PBT, polar body transfer; PNT, pronuclear transfer; ROS, reactive oxygen species; ST, spindle
transfer; SOD1, superoxide dismutase 1; TALENs, Transcription Activators like effector nucleases; [Ca2+]i, cytosolic calcium.
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the nuclear genomic material unaltered (Falk et al., 2016). This
is now known as mitochondrial replacement and the associated
techniques are known as mitochondrial replacement techniques
(MRT). Mitochondrial gene replacement in oocytes leads to
complete replacement of entire mtDNA, applicable to any
mtDNAmutation type and eliminates entire spectrum ofmtDNA
disease. Since genetic corrections will be heritable and passed on
to later generations, MRT prevents the need for repeated therapy
generation after generation. This significant progress raises the
hope that replacement of affected mitochondria in patient’s cells
can provide curative measures for several mitochondrial diseases.
In spite of various ethical and technical concerns, clinicians
see huge potential of MRT for cures of several devastating
mitochondrial diseases. In this opinion article we highlights
an update on new advances and implications of mitochondrial
therapy in neurodegenerative disorders and provide insights into
studies, suggesting limitations of this advance technology and its
future use in clinics. Our hope is that this article will provide a
platform for further critical discussion of this pertinent issue.
MITOCHONDRIAL DYSFUNCTION AND
NEURODEGENERATIVE DISEASES
Neurological diseases are heterogeneous in nature and affect
millions of people around the world. Genetic association studies
pinpointed ∼150 genetic diseases in which abnormalities in a
gene encoding a protein involve in regulation of mitochondria
(Calvo et al., 2016). For example, abnormalities in mitochondrial
functions have been attributed to be either a root cause or
a major driving mechanism involved in ALS disease (Jaiswal,
2013, 2014). In ALS, superoxide dismutase 1 (SOD1) has
been proven to be a key gene involved in the disease
pathogenesis (Jaiswal, 2012). SOD1 has been found to be
mutated in at least in ∼20% familial ALS (fALS) cases. Most
importantly, studies over the years have identified mitochondrial
dysfunction and associated oxidative stress, reactive oxygen
species (ROS) formation and calcium dysregulation to be
the critical effecter mechanism through which mutated SOD1
affects neuronal function and survival (Jaiswal and Keller,
2009; Jaiswal et al., 2009; Grosskreutz et al., 2010). Similarly,
in case of PD, scientists have focused on the function of
Parkin and PTEN-induced putative kinase 1 (PINK1), two
proteins mutated in familial, early-onset Parkinson’s disease
and recommended drugs for therapies that boost mitophagy
or stimulate activity of Parkin/PINK1 (Narendra and Youle,
2011). Recently it was shown that in autosomal dominant
HD where mhuntingtin (mHTT) mutated protein localizes to
the outer mitochondrial membrane, where it wields harmful
effects on mitochondria by diminishing mitochondrial motility,
alters mitochondrial morphology, fusion and fission, causes
calcium dysregulation, reduces oxidative phosphorylation, and
depolarizes the mitochondrial membrane potential in HD
patients (Reddy et al., 2009). Some of the therapeutic approaches
recently tested to target mitochondrial fission protein to which
mHTT binds, in mice and cells from humans with HD not only
curtailed the toxicity of HTT, but also restored normal motor
function in symptomatic HD mice (Song et al., 2011; Di Pardo
et al., 2012). Douglas Wallace discovered that mutation in one of
the mitochondrial tRNA genes precedes the pathological change,
which leads to mitochondrial dysfunction, are the hallmarks
of AD (Coskun et al., 2010). So, in general, dysfunctional
mitochondria are the hallmarks in the major neurodegenerative
diseases.
MITOCHONDRIAL DYNAMICS, TURN
OVER AND ITS ROLE IN
NEURODEGENERATIVE DISEASES
Mitochondria have turn over with a half-life of ∼25 days
in neurons (Menzies and Gold, 1971). Neurons, like other
cells critically depend upon mitochondrial functions for long-
distance transport of mitochondria to the synapse, isolation
and removal of faulty mitochondria from synaptic sites and
metabolic demands that require high bioenergetic outputs and
often associated with enhanced production of ROS. Continuous
buildup of ROS leads to oxidative damage and impaired protein
homeostasis within mitochondrial micro-domains (Lin and
Beal, 2006; Jaiswal, 2013, 2014). Therefore, mitochondria have
internal “mitochondrial quality control (MQC)” machinery to
maintain a vigorously functional, and healthy mitochondrial
number and mtDNA mutations by versatile proteolytic enzymes
and exchange of components during fusion/fission to maintain
normal function (Rugarli and Langer, 2012). Asymmetric
fission mechanism segregate damaged components into one
daughter mitochondrion, which is removed by autophagy (Twig
et al., 2008). Moreover, during fusion/fission mitochondria
form a tubular network via a dynamic process and dictated
by the fine balance between mitochondrial fusion and fission.
Altered balance of mitochondrial dynamics leads to pathogenesis
of complex neurodegenerative disorders such ALS, AD, PD,
and HD. For details see Burté et al. (2015). Selective
mitochondrial mitophagy removes damaged mitochondria and
closely associated to biogenesis, which permits replacement of
mitochondria and assembly of multiple mitochondrial proteins
(Kim and Lemasters, 2011). Thus, maintenance of protein
homeostasis through MQC is one of the key aspects in
preservation of functional integrity of neuronal mitochondria
(Bohovych et al., 2016). MQC involved in removal of impaired
misfolded proteins and regulation of assembly, maturation and
cleavage of proteins.
MITOCHONDRIAL
RESUSCITATION/REPLACEMENT IN
NEURODEGENERATIVE DISORDERS
Although many new candidate drugs or treatment strategies
are well on the way, unfortunately the fact remains that
there is still not a single broadly applicable effective cure
available for ALS, MS, PD, HD, and AD. Moreover, those
suffering from familial neurodegenerative diseases and carries
the harmful mutations in their nuclear and mitochondrial
genetic materials face significant risk of passing over these
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fatal diseases to their children. Thus, many individuals with
genetic predisposition and mutated mtDNA combined with
other contributing factors are likely to be affected ruining
their life without any hope for cure. Therefore, there are
eminent needs to find cure for such neurodegenerative
diseases. While approaches such as gene therapy or other
techniques will be needed for correcting the harmful errors
in nuclear genome, recent advancements now provides the
opportunity to correct the errors in the mitochondrial genetic
material applying different versions of recently developed MRT
procedures. We can think of two different modes of applying the
related therapeutic approaches, (a) preventive and (b) curative
(Figure 1).
In case of different neurodegenerative diseases with known
mutation in mtDNA, corrective measures such as mitochondrial
replacement by in vitro fertilization can serve as preventive cure.
As a preventive measure, MRT can be applied to replace
the dysfunctional mitochondria in the germ line cells thereby
avoiding harmful presence of the faulty mitochondrial genes in
the children. This can be achieved by harvesting and transferring
the nucleus of a woman carryingmtDNAmutations to the eggs of
a woman donor with healthy mtDNA to be fertilized. This allows
the “original” mother to avoid transmitting faulty mitochondrial
genes to the fetus, which inherit all mtDNA from the egg. An
alternative method involves fertilizing eggs from both women
in-vitro. Then, physicians remove and transfer chromosomes
FIGURE 1 | Mitochondrial replacement for neurodegenerative diseases. (A) Problems associated with mutations in mitochondrial DNA leads to generation of
toxic ROS which impair calcium homeostasis. Oxidative stress build up, in turns impair balance between fusion and fission of mitochondria accelerating vicious cycle
of mitochondrial damage ultimately affecting survival and function of neurons and results in cell death leading to many neurodegenerative diseases. (B) MRT currently
involves different strategies such as pronuclear transfer (PNT), spindle transfer (ST) (C) polar body transfer and other related techniques for mitochondrial
modifications. Pronuclei (PN) are membrane-enclosed entities in the zygote of mammals that house the male and female chromosomal contributions. In PNT,
pronuclei are removed from single-cell stage embryo at day one and transferred to a second embryo created using a donor egg with healthy mitochondria. This
tailored embryo can develop and transferred into mother. In ST technique, first spindle from donor and mtDNA-carrying unfertilized oocytes are extracted into
karyoplasts and thereafter karyoplasts from patient oocytes are fused to donor cytoplasts and fertilized with the partner’s sperm to create mtDNA-mutation free
embryos. During meiosis, mammalian oocytes undergoes two reductive divisions with uneven cytoplasmic segregration giving rise to two small cells containing DNA
known as polar bodies (PB)s which eventually disintegrates. The first PB (PB1) contains a diploid set of chromosome whereby the second polar body (PB2) contains a
haploid set. In PBT techniques, transfer of PB1 and PB2 into appropriate oocyte or zygotic cytoplasm supports the normal completion of meiosis giving rise to the
viable offspring after completion of its full term development. Advance genomics tools such as Transcription Activators like effector nucleases (TALENs), and
CRISPR/Cas edited iPS cells with corrected mutations in mitochondrial DNA possibly can overcome some of technical challenges MRT facing right now. MRT can be
achieved by germ cell (preventive) and stem cell (curative) modifications. (C) Major challenges of MRT are: (a) heteroplasmy and reversal, (b) incompatibility and
alloreactivity, (c) inapplicability of some techniques in human cells, and (d) accumulated mutations in mitochondria.
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from the nucleus of one egg to the egg from the woman with
healthy mitochondria. This technique is dubbed by the media as
“three-parent in-vitro-fertilization.”
Currently, three established techniques for mitochondrial
replacement exist for germ line therapies to circumvent mtDNA
based disease transmission: (1) pronuclear transfer (PNT,
McGrath and Solter, 1983; Craven et al., 2010), (2) spindle
transfer (ST, Tachibana et al., 2009; Cohen and Alikani, 2013;
Tachibana et al., 2013), and (3) polar body transfer (PBT;
Wang et al., 2014; Wolf et al., 2015). In PNT, pronuclei
are removed from single-cell stage embryo at day one and
transferred to a second embryo created using a donor egg
with healthy mitochondria. In ST technique, first spindle from
donor and mtDNA-carrying unfertilized oocytes are extracted
into karyoplasts and thereafter karyoplasts from patient oocytes
are fused to donor cytoplasts and fertilized with the partner’s
sperm to create mtDNA-mutation free embryos. Whereas in
PBT techniques, first or second polar bodies are transfer into
appropriate oocyte or zygotic cytoplasm supports the normal
completion of meiosis giving rise to the viable offspring after
completion of its full term development.
These techniques have distinct advantages and disadvantages.
In the recent years, these techniques have matured and have
been tested in various model organisms with some degree of
success. Recent PNT results between zygotes and nuclear spindles
among oocytes suggest the possibility of its use in humans
(Tachibana et al., 2009; Paull et al., 2013). Apart from the above-
mentioned preventive application, mitochondrial replacement
can also serve as a curative strategy. For this, MRT can be applied
to manipulate harvested stem cells collected from patients and
thereafter doing the homologous stem cell transplantation after
correcting the mitochondrial defects. It is important to mention
that recently scientist successfully demonstrated that genetically
corrected induced pluripotent stem cells (iPSCs) can be created
from fibroblasts from patients with mitochondrial mutations
(Ma et al., 2015). A similar approach has been tested earlier on
macaques produced normal offspring (Tachibana et al., 2009).
These discoveries indicate the feasibility of such techniques for
future therapeutic approaches.
TECHNICAL CHALLENGES, CONCERNS
AND RECENT ADVANCEMENTS
While recent developments in the field of MRT raising high
hope for cure, there remain major technological challenges and
concerns as outlined below.
Heteroplasmy and Reversal
Mitochondria constantly undergo fusion and fission (Karbowski
and Youle, 2003; Youle and van der Bliek, 2012). Moreover,
during mitochondrial transfer chances of those residual damaged
mitochondria remains in the cells can compromise the
effectiveness and long-term benefit of the MRT. As a result, a
prerequisite for ensuring successful and effective replacement of
damaged mitochondria is avoiding or critically minimizing the
carryover of damaged mitochondria. Most effective replacements
of damage mitochondria are thus needed to circumvent this
problem and undesired effect. Prior work already showed that
different techniques has different efficacy in minimizing such
carryover. While in case of techniques such as ST, first polar body
transfer (PBT1) or PNT, chances of carry over and heteroplasmy
remains high, in case of second polar body transfer (PBT2) such
carry over remains below detection level and∼1% (Yamada et al.,
2016). Thus, in future PBT2 or other effective novel techniques
might serve as a technique of choice for MRT. A recently
published article reported improved PNT technique which solve
the problem of mitochondrial carry over and reduce the number
of defective mitochondria transferred along the nuclear DNA to
the donor cell (Hyslop et al., 2016).
Incompatibility and Alloreactivity
Since the conception of mitochondrial replacement as a strategy,
amajor concern has been the possible incompatibilities of donor’s
mitochondria with the nuclear from unrelated individuals.
However, there are no strong evidence available strongly
supporting this concern especially in case of human. Moreover,
current studies indicate persistent compatibility between nuclear
genome and donor’s mitochondria (Mitalipov and Wolf, 2014).
Apart from nuclear-mitochondrial compatibility, alloreactivity
also emerges as serious concern if adequate attention not paid
to avoid it. This aspect is especially relevant for future curative
applications to treat patients with modified stem cells after
mitochondrial replacement. However, established approaches
such as immune suppression might be able to provide us viable
solution to circumvent such undesired side effects if needed.
Moreover, inexpensive genetic testing and matched donors also
can provide us ways to prevent such mismatches as mean
to eliminate or reduce chances for such undesired immune
response.
Inapplicability of Certain Techniques in
Human Cells
A major concern that effectiveness of many of these associated
procedure has been mainly shown successfully in animal studies
and applicability of such procedure still remained to validated
in human. While future studies will be needed to achieve such
validation to confirm the applicability of such techniques, recent
studies using human cells shows the initial evidences for the
effectiveness of MRT in human (Yamada et al., 2016).
Accumulated Mutations in Mitochondria
from Aged Persons
A recent discovery on stem cell mitochondria points that iPS cells
clones derived from elderly adults show accumulation of DNA
mutations and therefore screening cell lines for mitochondrial
mutation is important for clinical use (Kang et al., 2016).
Findings came with major conclusions that iPS cells derived from
older patients tend to show DNA mutations which can impact
metabolic function in iPS cells. However, recent improvement
of PNT which solve the problem of mitochondrial carry over
reduce the risk of mutant mtDNA (Hyslop et al., 2016). It is
also important to mention that currently MRT experts think
that physiological behavior of mitochondria is very different in
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embryonic stem cells compared to normal human development
and mutations of iPS mitochondria might not be true for human
and therefore procedure is safe.
CONCLUSION AND FUTURE DIRECTIONS
In spite of all of the concerns, it seems MRT has considerable
potential for preventing and possibly curing certain forms
of neurodegenerative diseases caused due to damaged or
dysfunctional mitochondria. Bench-to-bedside implementation
of above-mentioned approaches will be based on information
from a variety of scientific data and clinical trials of safety and
efficacy. Mitochondrial replacement combined with stem cells
might provide us future cures at least to a subset of patients where
structural and functional mitochondria-derived abnormalities
dictate disease pathology and progression. One key factor for
success of this technology will be the cost effectiveness and
viability in clinical set ups. Technology is still maturing and
there are several concerns that need to be addressed regarding
the possible differences between the animal models, preclinical
studies and human clinical conditions. While this approach can
serve as a good alternative approach, it might have limited scope
considering the disease heterogeneity and multiple mode of the
disease pathogenesis. Nonetheless, even if the techniques can be
successfully implemented in few of the well-equipped centers
and clinical facilities, that still be extremely beneficial to patients
who are currently suffering without hope for a cure. Only long-
term studies can tell us for certain if the technique is mature
enough to be applied at broad scale in clinics. We also hope
there will be a consensus built across our society and political
arena on the use of MRT. Furthermore, we hope that the recent
and future developments of MRT research will further improve
the efficacy and safety of the related techniques and will provide
the therapeutic benefit to the affected individuals and to avoid
the transmission of such life threatening diseases in their future
generations.
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